share Cann Group’s (ASX: CAN) manufacturer has started making cannabis resin from the company’s plants, and it should be ready for sale by March. The resin needs to be tested for stability before being sold as oil and as an active pharmaceutical ingredient (API) for other products. These products are intended for sale in Australia and for export. IDT Australia (ASX:IDT) , a $33m pharmaceuticals manufacturer based in eastern Melbourne, has been posting videos on LinkedIn of its cannabis operations, which led to a 37 per cent spike in the price of Cann shares before it went into a trading halt yesterday. “This represents the first commercial-scale resin extraction from Australian grown cultivars,” Cann said in a statement. Other companies such as Little Green Pharma are making their own resin from own-grown plants, but on a small scale. Cann has several years worth of harvests under its belt, tens […]